Yongqiang Yu1, Weidong Dong, Xin Li, Enju Yu, Xiaorong Zhou, Shuhua Li. 1. Department of Otolaryngology, Beifang Hospital of Shenyang, 83 Wenhua Road, Shenhe District, Shenyang City, Liaoning Province, People's Republic of China 110015. chanpingwang@yahoo.ca
Abstract
OBJECTIVE: To investigate the relationship between oncogene protein expression and nasopharyngeal carcinoma outcome. DESIGN: Tumor samples from 51 patients with nasopharyngeal carcinoma were analyzed by immunohistochemical staining for expression of Bcl-2 and c-Myc protein before irradiation. Five-year follow-up data were available. RESULTS: Thirty-one (61%) of 51 tumors expressed Bcl-2 protein, and 29 (57%) of 51 tumors expressed c-Myc protein. In the Bcl-2+ group, 20 (65%) and 19 (61%) of 31 patients experienced recurrence or died, respectively, whereas only 7 (35%) and 5 (25%) of 20 patients with Bcl-2- tumors did so. On the other hand, patients with c-Myc+ tumors had lower recurrence and death rates (38% [11/29] and 34% [10/29], respectively) than those with c-Myc- tumors (73% [16/22] and 64% [14/22], respectively). A statistically significant association was confirmed between Bcl-2 and c-Myc positivity and patient outcome. CONCLUSION: Expression of Bcl-2 and c-Myc protein seems to be a useful marker to reflect irradiation response and to predict illness condition and patient outcome.
OBJECTIVE: To investigate the relationship between oncogene protein expression and nasopharyngeal carcinoma outcome. DESIGN: Tumor samples from 51 patients with nasopharyngeal carcinoma were analyzed by immunohistochemical staining for expression of Bcl-2 and c-Myc protein before irradiation. Five-year follow-up data were available. RESULTS: Thirty-one (61%) of 51 tumors expressed Bcl-2 protein, and 29 (57%) of 51 tumors expressed c-Myc protein. In the Bcl-2+ group, 20 (65%) and 19 (61%) of 31 patients experienced recurrence or died, respectively, whereas only 7 (35%) and 5 (25%) of 20 patients with Bcl-2- tumors did so. On the other hand, patients with c-Myc+ tumors had lower recurrence and death rates (38% [11/29] and 34% [10/29], respectively) than those with c-Myc- tumors (73% [16/22] and 64% [14/22], respectively). A statistically significant association was confirmed between Bcl-2 and c-Myc positivity and patient outcome. CONCLUSION: Expression of Bcl-2 and c-Myc protein seems to be a useful marker to reflect irradiation response and to predict illness condition and patient outcome.
Authors: Atsushi Imai; Benjamin D Zeitlin; Fernanda Visioli; Zhihong Dong; Zhaocheng Zhang; Sudha Krishnamurthy; Emily Light; Frank Worden; Shaomeng Wang; Jacques E Nör Journal: Cancer Res Date: 2011-12-08 Impact factor: 12.701
Authors: Ali Fendri; Christos K Kontos; Abdelmajid Khabir; Raja Mokdad-Gargouri; Alexandros Ardavanis; Andreas Scorilas Journal: Tumour Biol Date: 2010-06-01
Authors: Paul L Swiecicki; Emily Bellile; Assuntina G Sacco; Alexander T Pearson; Jeremy M G Taylor; Trachette L Jackson; Douglas B Chepeha; Matthew E Spector; Andrew Shuman; Kelly Malloy; Jeffrey Moyer; Erin McKean; Scott McLean; Ammar Sukari; Gregory T Wolf; Avraham Eisbruch; Mark Prince; Carol Bradford; Thomas E Carey; Shaomeng Wang; Jacques E Nör; Francis P Worden Journal: Invest New Drugs Date: 2016-05-26 Impact factor: 3.850